Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(32 sites) United States
Loma Linda University Cancer Center, Loma Linda, California UC Davis Comprehensive Cancer Center, Sacramento, California Sarah Cannon Research Institute at HealthONE, Denver, Colorado AdventHealth Celebration, Celebration, Florida University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida The University of Kansas Cancer Center, Kansas City, Kansas National Institutes of Health, Bethesda, Maryland Massachusetts General Hospital Cancer Center, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Karmanos Cancer Institute, Detroit, Michigan Memorial Sloan-Kettering Cancer Center, New York, New York The Ohio State University Comprehensive Cancer Center, Columbus, Ohio University of Oklahoma Health Sciences, Stephenson Cancer Center, Oklahoma City, Oklahoma Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville, Tennessee The University of Texas, MD Anderson Cancer Center, Houston, Texas UT Health Mays Cancer Center, San Antonio, Texas Fred Hutchinson Cancer Center, Seattle, Washington University of Wisconsin- Madison, Madison, Wisconsin Canada
Princess Margaret Cancer Centre, Toronto, Ontario Research Institute of McGill University Health Centre, Montreal, Quebec France
Hopsital Institut Curie, Paris, France Oncopole Claudius Regaud IUCT, Toulouse, France Institut Bergonié, Bordeaux Institute Gustave Roussy, Villejuif Spain
Vall d'Hebron Institute of Oncology, Barcelona, Catalonia Clinica Universidad de Navarra, San Blas-Canillejas, Madrid Hospital Universitario Quirónsalud Madrid, Madrid, Spain NEXT Oncology Barcelona, Hospital Quirónsalud Barcelona, Barcelona Clinica Universidad de Navarra, Pamplona Instituto de Investigacion Sanitaria, INCLIVA, Valencia